Tenderwize
Wróć do wyszukiwania

Discount agreements for Bevacizumab and Rituximab

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline May 10, 2028 · 573 days left·Open·Supplies
Zarejestruj się, aby zapisać
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V für die Wirkstoffe Bevacizumab und Rituximab

50/100

Ocena szansy

PromisingLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or discount terms are specified, making it difficult to assess financial attractiveness.

The notice does not specify how discount agreements are awarded or if price is a factor. In practice, all qualified bid...

No procurement documents available

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Najważniejsze informacje

Zamawiający
GWQ ServicePlus AG
Kraj
Niemcy
CPV
33600000 - Pharmaceutical products
Termin
May 10, 2028

Przegląd

Strong opportunity

Kluczowe fakty

  • Supplies contract
  • 2 lots
  • Duration until Jun 2028
  • Non-exclusive discount agreements for pharmaceutical products containing Bevacizumab and Rituximab
  • Open to all interested pharmaceutical companies (accession model)
Pokaż pełne podsumowanie

Non-exclusive discount agreements (Rabattvereinbarungen) under §130a Abs. 8 SGB V for the active ingredients Bevacizumab and Rituximab, organized by GWQ ServicePlus AG for German statutory health insurance funds. The procedure is open to all interested pharmaceutical companies on a non-discriminatory basis. The initial contract start is 1 July 2026, with a two-year term and an option to extend by 12 months. Contracts can be joined at any time during the term. The initial submission deadline for signed contracts is 10 June 2026.

Ryzyka

No estimated value or discount terms are specified, making it difficult to assess financial attractiveness.

The notice does not specify how discount agreements are awarded or if price is a factor. In practice, all qualified bid...

No procurement documents available

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company with marketing authorization for the respective active ingredient

Administrative

  • Submission of signed contract in duplicate, proof of marketing authorization, self-declarations (Annexes 6 and 7), and list of PZN (Annex 5)
  • Initial submission deadline: 10 June 2026 for first inclusion from 1 July 2026

Zamawiający

Lokalizacja

Düsseldorf, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE258895210

Działalność

Health

Części (2)

LOT-0001

Non-exclusive discount agreement for Bevacizumab

Non-exclusive discount agreement for the active ingredient Bevacizumab. Open to all pharmaceutical companies under an accession model. Initial contract start 1 July 2026 for 2 years, with option to extend by 12 months. Required documents: signed contract (2 copies), proof of marketing authorization from AMIce database, self-declaration (Annex 6), list of PZN (Annex 5), self-declaration on EU regulation (Annex 7). Submission via postal mail.

SuppliesEU fundedElectronic submission

Lokalizacja

DEA11, Germany

Czas trwania

Jun 2026 - Jun 2028

Kategoria

Pharmaceutical products

Termin

Expired Jun 10, 2026

LOT-0002

Non-exclusive discount agreement for Rituximab

Non-exclusive discount agreement for the active ingredient Rituximab. Open to all pharmaceutical companies under an accession model. Initial contract start 1 July 2026 for 2 years, with option to extend by 12 months. Required documents: signed contract (2 copies), proof of marketing authorization from AMIce database, self-declaration (Annex 6), list of PZN (Annex 5), self-declaration on EU regulation (Annex 7). Submission via postal mail.

SuppliesEU fundedElectronic submission

Lokalizacja

DEA11, Germany

Czas trwania

Jun 2026

Kategoria

Pharmaceutical products

Termin

Expired Jun 10, 2026

Szczegóły zamówienia

Data publikacji
26 May 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
362066-2026

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30